Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes

Volume: 120, Issue: 1-2, Pages: 57 - 61
Published: Jan 1, 2017
Abstract
Fabry disease (FD) is a rare X-linked lysosomal storage disorder due to mutations in the α-galactosidase A gene (GLA) that result in absent or markedly reduce α-galactosidase A (α-GalA) enzymatic activity. As a result, the major glycosphingolipid substrates, globotriaosylceramide (Gb3) and globotriaosylsphingosine (LysoGb3) accumulate in plasma, urine and tissue lysosomes. In females, the diagnosis can be complicated by the fact that 40–50% of...
Paper Details
Title
Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes
Published Date
Jan 1, 2017
Volume
120
Issue
1-2
Pages
57 - 61
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.